Skip to main content
. 2017 Oct 26;131(2):182–190. doi: 10.1182/blood-2017-09-804641

Table 3.

Response rates by disease status

Disease status No. CR PR Response rate (%) 95% CI
Rituximab naïve 3 1 1 66.7 9.4-99.2
Rituximab sensitive 19 3 7 52.6 28.9-75.6
Rituximab refractory 18 1 2 16.7 3.6-41.4
Chemotherapy sensitive* 26 4 7 42.3 23.4-63.1
Chemotherapy refractory* 14 1 3 28.6 8.4-58.1
*

On the basis of response to most recent prior chemotherapy.